Catalyst Pharmaceuticals Inc logo

CPRX - Catalyst Pharmaceuticals Inc Share Price

$3.39 -0.0  -0.9%

Last Trade - 17/09/20

Small Cap
Market Cap £270.4m
Enterprise Value £181.7m
Revenue £92.3m
Position in Universe 3260th / 6371
Unlock CPRX Revenue
Relative Strength (%)
1m -7.16%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -49.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.50 102.3 126.6 151.9
+32.4 +4.27
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Catalyst Pharmaceuticals Inc revenues increased 42% to $58.7M. Net income increased 96% to $20.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.10 to $0.20.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CPRX Revenue Unlock CPRX Revenue

Net Income

CPRX Net Income Unlock CPRX Revenue

Normalised EPS

CPRX Normalised EPS Unlock CPRX Revenue

PE Ratio Range

CPRX PE Ratio Range Unlock CPRX Revenue

Dividend Yield Range

CPRX Dividend Yield Range Unlock CPRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CPRX EPS Forecasts Unlock CPRX Revenue
Profile Summary

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated July 21, 2006
Public Since November 8, 2006
No. of Shareholders: 34
No. of Employees: 76
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 103,463,460
Free Float (0.0%)
Eligible for
CPRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CPRX
Upcoming Events for CPRX
Frequently Asked Questions for Catalyst Pharmaceuticals Inc
What is the Catalyst Pharmaceuticals Inc share price?

As of 17/09/20, shares in Catalyst Pharmaceuticals Inc are trading at $3.39, giving the company a market capitalisation of £270.4m. This share price information is delayed by 15 minutes.

How has the Catalyst Pharmaceuticals Inc share price performed this year?

Shares in Catalyst Pharmaceuticals Inc are currently trading at $3.39 and the price has moved by -48.17% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Catalyst Pharmaceuticals Inc price has moved by -53.96% over the past year.

What are the analyst and broker recommendations for Catalyst Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Catalyst Pharmaceuticals Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Catalyst Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Catalyst Pharmaceuticals Inc next release its financial results?

Catalyst Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Catalyst Pharmaceuticals Inc dividend yield?

Catalyst Pharmaceuticals Inc does not currently pay a dividend.

Does Catalyst Pharmaceuticals Inc pay a dividend?

Catalyst Pharmaceuticals Inc does not currently pay a dividend.

When does Catalyst Pharmaceuticals Inc next pay dividends?

Catalyst Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Catalyst Pharmaceuticals Inc shares?

To buy shares in Catalyst Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Catalyst Pharmaceuticals Inc?

Shares in Catalyst Pharmaceuticals Inc are currently trading at $3.39, giving the company a market capitalisation of £270.4m.

Where are Catalyst Pharmaceuticals Inc shares listed? Where are Catalyst Pharmaceuticals Inc shares listed?

Here are the trading details for Catalyst Pharmaceuticals Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CPRX
What kind of share is Catalyst Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Catalyst Pharmaceuticals Inc is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Catalyst Pharmaceuticals Inc share price forecast 2020?

Shares in Catalyst Pharmaceuticals Inc are currently priced at $3.39. At that level they are trading at 0.124% discount to the analyst consensus target price of 0.00.

Analysts covering Catalyst Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.398 for the next financial year.

How can I tell whether the Catalyst Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Catalyst Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -24.05%. At the current price of $3.39, shares in Catalyst Pharmaceuticals Inc are trading at -19.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Catalyst Pharmaceuticals Inc PE Ratio?

The Catalyst Pharmaceuticals Inc PE ratio based on its reported earnings over the past 12 months is 8.67. The shares are currently trading at $3.39.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Catalyst Pharmaceuticals Inc?

Catalyst Pharmaceuticals Inc's management team is headed by:

Patrick McEnany - CHM
Charles O'Keeffe - LED
David Tierney - IND
Steven Miller - COO
Alicia Grande - CFO
Richard Daly - IND
Donald Denkhaus - IND
Gary Ingenito - OTH
Brian Elsbernd - CCO
Jeffrey Del Carmen - OTH
Who are the major shareholders of Catalyst Pharmaceuticals Inc?

Here are the top five shareholders of Catalyst Pharmaceuticals Inc based on the size of their shareholding:

State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 6.45% (6.68m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.28% (6.50m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 5.99% (6.20m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.92% (5.09m shares)
SPDR S&P Biotech ETF Mutual Fund
Percentage owned: 4.77% (4.93m shares)
Similar to CPRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.